Cargando…
Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783257/ https://www.ncbi.nlm.nih.gov/pubmed/31847652 http://dx.doi.org/10.1177/0300060519887276 |
_version_ | 1783632077744242688 |
---|---|
author | Liu, Ying-ying Chen, Tao Shen, Dan Zhang, Wei-yun Wang, Chang-guo Jiang, Jun-hong Zeng, Da-xiong |
author_facet | Liu, Ying-ying Chen, Tao Shen, Dan Zhang, Wei-yun Wang, Chang-guo Jiang, Jun-hong Zeng, Da-xiong |
author_sort | Liu, Ying-ying |
collection | PubMed |
description | The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand–foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy. |
format | Online Article Text |
id | pubmed-7783257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77832572021-01-13 Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review Liu, Ying-ying Chen, Tao Shen, Dan Zhang, Wei-yun Wang, Chang-guo Jiang, Jun-hong Zeng, Da-xiong J Int Med Res Case Report The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand–foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy. SAGE Publications 2019-12-18 /pmc/articles/PMC7783257/ /pubmed/31847652 http://dx.doi.org/10.1177/0300060519887276 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Liu, Ying-ying Chen, Tao Shen, Dan Zhang, Wei-yun Wang, Chang-guo Jiang, Jun-hong Zeng, Da-xiong Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review |
title | Low-dose apatinib monotherapy in advanced chemotherapy-refractory
small cell lung cancer: a case series and literature review |
title_full | Low-dose apatinib monotherapy in advanced chemotherapy-refractory
small cell lung cancer: a case series and literature review |
title_fullStr | Low-dose apatinib monotherapy in advanced chemotherapy-refractory
small cell lung cancer: a case series and literature review |
title_full_unstemmed | Low-dose apatinib monotherapy in advanced chemotherapy-refractory
small cell lung cancer: a case series and literature review |
title_short | Low-dose apatinib monotherapy in advanced chemotherapy-refractory
small cell lung cancer: a case series and literature review |
title_sort | low-dose apatinib monotherapy in advanced chemotherapy-refractory
small cell lung cancer: a case series and literature review |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783257/ https://www.ncbi.nlm.nih.gov/pubmed/31847652 http://dx.doi.org/10.1177/0300060519887276 |
work_keys_str_mv | AT liuyingying lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview AT chentao lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview AT shendan lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview AT zhangweiyun lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview AT wangchangguo lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview AT jiangjunhong lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview AT zengdaxiong lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview |